发明授权
US09090667B2 Cyclic peptide from Nonomuraea sp., process for the production thereof, and pharmaceutical composition for the prevention or treatment of mycobacteria related disease comprising the same
有权
来自Nonomuraea sp。的环肽，其制备方法，以及用于预防或治疗包含其的分枝杆菌相关疾病的药物组合物
- 专利标题： Cyclic peptide from Nonomuraea sp., process for the production thereof, and pharmaceutical composition for the prevention or treatment of mycobacteria related disease comprising the same
- 专利标题（中）： 来自Nonomuraea sp。的环肽，其制备方法，以及用于预防或治疗包含其的分枝杆菌相关疾病的药物组合物
-
申请号： US14112720申请日： 2012-04-18
-
公开(公告)号： US09090667B2公开(公告)日： 2015-07-28
- 发明人: Jong Woo Kim , Sang Wook Lee , Sang Jin Park , Joo Won Suh , In Ae Lee , Tae Mi Yoon , Jong Keun Choi , Ji Ean Lee , Jin Yong Kim , Ying Yu Jin , Scott Franzblau , Sanghyun Cho , Wei Gao , Guido Pauli , James McAlpine , Jose Napolitano , Birgit Jaki , Brent Friesen , Maria Florencia Rodriguez Brasco , David Lankin
- 申请人： Jong Woo Kim , Sang Wook Lee , Sang Jin Park , Joo Won Suh , In Ae Lee , Tae Mi Yoon , Jong Keun Choi , Ji Ean Lee , Jin Yong Kim , Ying Yu Jin , Scott Franzblau , Sanghyun Cho , Wei Gao , Guido Pauli , James McAlpine , Jose Napolitano , Birgit Jaki , Brent Friesen , Maria Florencia Rodriguez Brasco , David Lankin
- 申请人地址： KR Gyeonggi-do US IL
- 专利权人： Myongji University Industry and Academia Cooperation Foundation,The Board of Trustees of the University of Illinois
- 当前专利权人： Myongji University Industry and Academia Cooperation Foundation,The Board of Trustees of the University of Illinois
- 当前专利权人地址： KR Gyeonggi-do US IL
- 代理机构： Rabin & Berdo P.C.
- 国际申请： PCT/KR2012/002933 WO 20120418
- 国际公布： WO2012/144790 WO 20121026
- 主分类号： C07K7/54
- IPC分类号： C07K7/54 ; C07K7/08 ; A61K38/00
摘要：
The present invention relates to novel anti-TB cyclic peptides from Nonomuraea sp. MJM5123, a process for the production of the anti-Tuberculosis peptide and a pharmaceutical composition for the prevention and treatment of mycobacterial infection comprising the same. The composition of the present invention is highly active against replicating/non-replicating M. tuberculosis, including MDR and XDR strains, so that it can be effectively used as a therapeutic agent for tuberculosis.